RHPS4 - CAS:390362-78-4

您当前的位置：

RHPS4

目录号 : KM5333 CAS No. : 390362-78-4 纯度 : 98%

Data Sheet 产品使用指南

RHPS4 是有效的端粒酶 (telomerase) 抑制剂 (IC50 = 0.33 μM)。RHPS4 是 DNA 损伤的诱导剂。

规格	价格	是否有货
5mg		In-stock
10mg		In-stock
25mg		In-stock
50mg		In-stock
100mg	询价	In-stock
200mg	询价	In-stock

查看所有商品（1）

加入购物车大包装询价

Other Forms of Rapamycin:

MY-1076 In-stock
Oxamic acid In-stock
FG-3019 In-stock
Hematoporphyrin monomethyl ether In-stock
Dibromoacetic acid In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

RHPS4 is a potent telomerase inhibitor (IC₅₀ = 0.33 μM). RHPS4 is a DNA damage inducer.

体外研究

RHPS4 could sensitize tumor cells to anticancer agents that act via disparate mechanisms.
RHPS4 (0.5-1 μM, 15 days) induces a senescent-like growth arrest in MCF-7 cells.
RHPS4 (1 μM, 4 days) induces phosphorylation of H2AX in transformed and tumor cells.

Cell Proliferation Assay

Cell Line:	MCF-7, MCF-7 vector control, and MCF-7 c81 cells.
Concentration:	0, 0.2, 0.5, or 1 μM.
Incubation Time:	7 days.
Result:	Inhibited cell proliferation.

体内研究

RHPS4 (15 mg/kg, iv, 15 days) treatment produces a marked inhibition of tumor weight (tumor weight inhibition [TWI] about 80%; P < 0.001) in a very short time, and this effect persists for at least 30 days. A complete tumor response is observed in 80% of mice, and 40% are cured.
In all the other tumor xenografts, RHPS4 treatment produces about 50% (P < 0.001) TWI at the nadir of the effect and, more important, results in a delay of tumor growth of about 15 (M14 and PC3) and 10 (HT29 and H460) days.

Animal Model:	CD-1 male nude (nu/nu) mice, 6–8 weeks old and weighing 22-24 g (H460, CG5 and HT29, PC3 and M14 cancer models).
Dosage:	15 mg/kg.
Administration:	IV, daily for 15 consecutive days.
Result:	Active as a single agent on all the tumors analyzed. CG5 breast xenografts resulted in the most sensitive tumor.

分子式

C₂₃H₂₀F₂N₂O₄S

分子量

458.48

CAS号

390362-78-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 1 mg/mL (2.18 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1811 mL	10.9056 mL	21.8112 mL
5 mM	---	---	---
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 1.25 mg/mL (2.73 mM); Suspended solution; Need ultrasonic

此方案可获得 1.25 mg/mL (2.73 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。